

STRONG MOLECULAR IMMUNOLOGY EVIDENCES ALLOW FOR HYPOTHESIS OF AN EXISTENCE OF A REVERSE PATHWAY (RP) WHICH PASSES GENETIC INFORMATION FROM POLYPEPTIDE ANTIGENS TO VDJ SECTION OF Ig GENE IN B-LYMPHOCYTES

By Victor Alexander, PhD., Independent Researcher, and Seveen Alexander (Pharmacy doctoral student of CA Northstate University, College of Pharmacy).

Abstract

Current Clonal Selection Theory fails to adequately explain the presence of a “hyper mutation” particularly in 3 CDR sections of a V part of Ig genes, which are responsible for recognition and binding of antigens with a high affinity, the degree of wastefulness of random rearrangements of Ig genes in B- lymphocytes and a standard formation of four special recognition palindromic sequences after the 1st V-D-J rearrangement.

The precision of the process allows for a hypothesis of an existence of a Reverse Pathway(RP) in B-lymphocytes which passes the exact genetic information from polypeptide antigens back to DNA, permitting for versatility and quick reaction in B-lymphocytes in response to foreign antigens.

The discovery of such a pathway will, undoubtedly, challenge the current Clonal Selection Theory of Immunology as well as the (current) Central Dogma of Molecular Biology which has established the DNA ⇌ RNA ⇒ Protein pathway of genetic information. It is our hope that our pioneering Reverse Pathway Research Project will prove that the genetic information can follow by both directions: DNA ⇌ RNA ⇌ Protein.

The discovery of such a reverse pathway will allow for a new, more effective and affordable treatment methods for curing many of the immune related diseases as well as cancer.

Molecular Immunology Evidences that Speak on Behalf of an Existence of a Reverse Pathway:

The following evidences point to an existence of a Reverse Pathway mechanism which passes an exact genetic information to VDJ (VJ) region of rearranged V parts of Ig genes:

1. “Hypermutation” of Ig gene is not clearly explainable (1,2,3)
2. “Hypermutation” of Ig genes is localized mostly in 3 CDRs of V parts of H and L chains of Ig genes (1, 2)
3. Creations of 2 and 4 standard Palindromic Recognition Segments (PRS) in VDJ and VJ regions of rearranged Ig genes also show existence of undiscovered yet RP mechanism. (2).
4. Wastefulness of “random” rearrangements of VDJ and VJ regions of Ig genes of all B-Lymphocytes also speak against accepted point of view.
5. At high concentrations TI-1 antigens are stimulating proliferation and antibody secretion by as many as one third of all B-cells also couldn’t explain by random rearrangements theory . (2)

Explanation of Main Steps of Reverse Pathway Hypothesis:

Pattern (first) re-arrangement:

According to our hypothesis, the first rearrangement of V-D-J sequences of V parts of Ig Genes in pro- and pre-Lymphocytes that occurs in a bone marrow is not a “random” rearrangement, but a Pattern rearrangement!

Because of some of pattern antigens encounter repeatedly in some of the Microbes groups and are the same and characteristic for these group of Microbes, evolution of Immune System had created Toll Like Receptors (TLRs) for quick reacting to these pattern antigens.

According to our hypothesis existing of numerous v-exons in the V parts of H and L chains in B-Lymphocytes are also pattern exons corresponding to different pattern antigens! Therefore after getting corresponding TLRs pathway signaling through cytokines, chemokine produced by Macrophage and Stromal Cells of Bone Marrow, V parts of Ig genes of pro, pre-B-Lymphocytes exactly choose corresponding v-exon from the existing repertoire of V section of Ig genes and undergo to first pattern rearrangement! It is not random rearrangement!

Such rearrangement produces specific IgM for the type of pattern antigens, however it lacks the high degree of affinity towards to many unknown polypeptide antigens on microbes .

The first pattern rearrangement of V(D)J sequences of Ig genes creates 2-4 Palindromic Signal Sequences which later allow mature lymphocytes to replace nucleotides between palindromic sequences to nucleotides which code for higher affinity amino acids sequences to an antigen using genetic information coming through Reverse Pathway (will explain later). (fig.1) (2)

Figure 1. VDJ sequence after 1st rearrangement

- After making stalk between 2 palindromic heptamers and 2 nonamers (1-term RSS+ 2 term RSS) and cutting them together with intervening sequences of 12+23 bps (7bp+9bp +12bp+23 bp)=51 bpx2=102bp by Recombinase (RAG-1;-2 encoded enzymes) between V_H---D---J_H, endonucleases cut hairpins and repair enzymes generates 4 palindromic bps and TdT adds 2 N- nucleotides (up to 15 nucleotides) between

V_H-p-N- p-D-p-N- p-J_H

- Since this diversity occurs at VDJ coding joints, it is localized in **CDR-3** of the Heavy chain genes!

Reverse Pathway Replacement (Affinity Maturation):

RP replacement of nucleotides in V(D)J regions of Ig genes to yield a higher affinity immunoglobulin, takes place in germinal centers of secondary lymphoid tissues, such as lymph nodes or spleen, based on the exact genetic information received from MHC-2:antigen (or MHC-1:antigen?) complexes on B-lymphocytes by undiscovered yet Reverse Pathway mechanism.

The proposed mechanism of a Reverse Pathway, although needs further research confirmation, is as follows. Initially mature B-cells internalize the antigen by it’s new but less affine membrane bound IgM. In endosome-lysosome of B-cell antigen is digested by hydrolytic enzymes to small polypeptides and connected with MHC-2 in B-cells. Then, in special endosome, small antigen polypeptide on MHC-2 create non-covalent affinity connections with activated amino acids-t-RNA complexes. Following that, a unknown yet RNA –Protein Enzyme Complex (Reverse Ribosome?!) cuts and connect anti-codons of t-RNA of matching activated amino-acids to antigen amino-acids and that way creates an exact RNA template of polypeptide of high affinity to antigen (fig.2), which connects with two nuclear receptors dimers and moves to nucleus of B-lymphocytes. In the nucleus, it connects with the two Palindromic Recognition Sequences (PRS) of VDJ (VJ) parts of Ig Genes. Then, an endonuclease cuts Genomic DNA between 2 palindromic sequences in VDJ (VJ) section of Ig genes and DNA repair enzymes replace nucleotides using the template RNA which is carrying high affinity genetic information about the antigen to VDJ (VJ) segments of Ig genes. After that, there is going class switching and transcription of high affinity IgG m-RNA and translation of high affinity IgG to given antigen (see: fig.3).

Figure 2. A proposed mechanism for creation of an antigen-based template RNA.





Figure 3. Replacing of the sequences coding for a high affinity Ig into the VDJ section of Ig gene



References

1. Grace Teng and F. Nina Papavasiliou " Immunoglobulin Somatic Hypermutation" Laboratory of Lymphocyte Biology, The Rockefeller University, New York 10021; Annu. Rev. Genet. 2007. 41:107-20
2. Richard Goldsby, Thomas Kindt, Barbara Osborne, Janis Kubu, Immunology, chapter 5, pp. 105-128; chapter 7, pp 176-177; chapter 9, p.218; chapter 11, pp. 269-270, Book, Fifth edition, 2003.
3. Ziqiang Li1, Caroline J. Woo1, Maria D. Iglesias-Ussel, Diana Ronai, and Matthew D. Scharff., The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes & Dev. 2004. 18: 1-11
4. Wallén-Ohman M, Larriek JW, Carlsson R, Borrebaeck CA., Ligation of MHC class I induces apoptosis in human pre-B cell lines, in promyelocytic cell lines and in CD40-stimulated mature B cells., Department of Immunotechnology, Lund University, Sweden., Int Immunol. 1997 Apr;9(4):599-606.
5. Mayumi M, Ohshima Y, Hata D, Kim KM, Heike T, Katamura K, Furusho K. Department of Pediatrics, Kyoto University, Japan. IgM-mediated B cell apoptosis. Crit Rev Immunol. 1995;15(3-4):255-69.
6. Houlden BA, Widacki SM, Bluestone JA. , Committee on Immunology, University of Chicago, Ben May Institute, IL 60637. Signal transduction through class I MHC by a monoclonal antibody that detects multiple murine and human class I molecules. J Immunol. 1991 Jan 15;146(2):425-30.
7. Gur H, Geppert TD, Wacholtz MC, Lipsky PE., The Harold C. Simmons Arthritis Research Center and The Division of Rheumatic Diseases, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75235, USA., The cytoplasmic and the transmembrane domains are not sufficient for class I MHC signal transduction. Cell Immunol. 1999 Feb 1;191(2):105-16.
8. Pedersen AE, Skov S, Bregenholt S, Ruhwald M, Claesson MH., Department of Medical Anatomy, The Panum Institute, The University of Copenhagen, Denmark., Signal transduction by the major histocompatibility complex class I molecule., APMSIS. 1999 Oct; 107(10):887-95.
9. Hannier S, Triebel F., Laboratoire d'Immunologie Cellulaire, Institut Gustave-Roussy, and Laboratoire d'Immunologie des tumeurs, Faculté de Pharmacie, Université Paris XI, 92296 Chatenay-Malabry, France., The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes., Int Immunol. 1999 Nov;11(11):1745-52.
10. Kevin R. Bobbitt* and Louis B. Justement, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, and Division of Developmental and Clinical Immunology, Department of Microbiology, University of Alabama, Birmingham, AL 35294, Regulation of MHC Class II Signal Transduction by the B Cell Coreceptors CD19 and CD221, The Journal of Immunology, November 15, 2000 vol. 165 no. 10 5588-5596
11. Nemazee D, Gavin A, Hoebe K, Beutler B., Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA., Immunology: Toll-like receptors and antibody responses., Nature. 2006 May 18;441(7091):E4; discussion E4.
12. Pasare C, Medzhitov R., Howard Hughes Medical Institute and Section of Immunobiology, Yale University School of Medicine, 300 Cedar Street New Haven, Connecticut 06510, USA., Control of B-cell responses by Toll-like receptors., Nature. 2005 Nov 17;438(7066):364-8.
13. Marron TU, Yu JE, Cunningham-Rundles C., Mount Sinai School of Medicine, New York, New York 10029, USA., Toll-like receptor function in primary B cell defects., Front Biosci (Elite Ed). 2012 Jan 14;1853-63.
14. Khan WN., Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232-5632, USA., Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase., Immunol Res. 2001;23(2-3):147-56.
15. Kiyoshi Takeda1,2, Tsuneyasu Kaisho1,2,3, and Shizuo Akira1,2,; 1Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Suita Osaka 565-0871, Japan, 2Solution Oriented Research for Science and Technology, Japan Science and Technology Corporation, Suita Osaka 565-0871, Japan; 3RIKEN Research Center for Allergy and Immunology, Suita Osaka 565-0871, Japan, TOLL-LIKE RECEPTORS, Annual Review of Immunology, Vol. 21: 335-376 (Volume publication date April 2003)
16. Li X, Jiang S, Tapping RI (2010) Toll-like receptor signaling in cell proliferation and survival. Cytokine 49(1), 1–9.
17. Pasare C, Medzhitov R (2005) Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560, 11–8.
18. Olga DelaRosa,1 Wilfried Dalemans,2 and Eleuterio Lombardo1, Toll-Like Receptors as Modulators of Mesenchymal Stem Cells, Front Immunol. 2012; 3: 182., Published online 2012 July 2
19. Krisztian Nemeth, corresponding author Balazs Mayer, and Eva Mezey, Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands, J Mol Med (Berl). 2010 January; 88(1): 5–10.
20. John Slagg, Sandra Pommey, Nicoletta Eliopoulos, and Jacques Galipeau, Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell, Blood March 15, 2006 vol. 107 no. 6 2570-2577
21. Emer Bourke, Daniela Bosisio, Josée Golay, Nadia Polentarutti, and Alberto Mantovani, Department of Immunology and Cell Biology, Mario Negri Institute; and the Centro IDET Istituto di Patologia Generale, Università di Milano, Milan, Italy., The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells., Blood, August 1, 2003 vol. 102 no. 3 956-963
22. Elize A. Hayashi*, Shizuo Akira† and Alberto Nobrega2,*, Department of Immunology, Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; †Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, and Exploratory Research for Advanced Technology, Japan Science and Technology Agency, Osaka, Japan., Role of TLR in B Cell Development: Signaling through TLR4 Promotes B Cell Maturation and Is Inhibited by TLR21, The Journal of Immunology June 1, 2005 vol. 174 no. 11 6639-6647
23. Marta Muzio, Eleonora Fonte and Federico Caligaris-Cappio, Division of Molecular Oncology, San Raffaele Scientific Institute, Milano, Italy., 2Università degli Studi di Pavia, Pavia, Italy. Toll-like Receptors in Chronic Lymphocytic Leukemia., Mediterr J Hematol Infect Dis 2012, 4(1): e2012055, DOI: 10.4084/MJHID.2012.0055

Future Directions:

After discovering of RP will be begun experiments inflicting of damages to different steps of RP and corrections of these damages. Results of this research will bring new more effective treatment methods of many immune related diseases, including cancer.